By Dr. Yahia Anane, PhD
A new drug just made headlines. Daraxonrasib, a targeted therapy for KRAS-mutant pancreatic cancer, doubled median survival — from 6.7 months to 13.2 months.
The medical world is celebrating. Major publications are calling it a breakthrough.
To me, it is not impressive.
Doubling a number that started at 6.7 months still leaves patients with a median of just over a year to live. The drug costs hundreds of thousands of dollars per course of treatment. And it only works in patients with a specific KRAS mutation.
Meanwhile, there is a drug that costs pennies a day, attacks pancreatic cancer through completely different mechanisms, and the medical system will not even mention it.
That drug is mebendazole.
Why Pancreatic Cancer Is So Hard to Treat
Pancreatic cancer has one of the worst survival rates of any cancer — a 5-year survival of around 3%.
The reason is something called desmoplasia.
Pancreatic tumors surround themselves with a dense, fibrous shield made of collagen, stromal cells, and extracellular matrix. This shield is so thick and so protective that it physically blocks chemotherapy, immunotherapy, and targeted drugs from reaching the cancer cells inside.
You can give the most powerful drug in the world, and most of it never touches the tumor.
This is why every conventional treatment for pancreatic cancer underperforms. It is not that the drugs don’t work. It is that they never arrive.
Daraxonrasib does not solve this problem. It just happens to be one of the few drugs that can penetrate the shield in some patients with a specific mutation.
Mebendazole solves the problem differently. It dismantles the shield itself.
What Mebendazole Actually Does
1. It dismantles the desmoplastic shield
This is the headline.
A Johns Hopkins study found that mebendazole significantly reduced fibrotic connective tissue around pancreatic tumors, suppressed tumor growth, and decreased liver metastasis.
When the shield comes down, everything else works better:
- Chemotherapy can penetrate
- Immune cells can reach the tumor
- Other repurposed drugs become more effective
- Oxygen flow improves
- Drug resistance drops
Mebendazole is not just an anti-cancer drug. It is a shield-breaker — and that may be its most important function in pancreatic cancer.
2. It arrests cancer cell division
Mebendazole binds to β-tubulin and disrupts microtubule formation — the internal scaffolding cancer cells need to divide. Without functional microtubules, cancer cells cannot complete mitosis. They stall, then die.
3. It reactivates p53
p53 is the body’s master tumor suppressor — the gene that detects damaged cells and orders them to self-destruct. In most pancreatic cancers, p53 is suppressed or mutated. Mebendazole has been shown to reactivate functional p53 signaling, restoring the cancer cell’s natural death program.
4. It blocks STAT3 and NF-κB
These are two of the master survival switches in cancer. STAT3 drives proliferation and stemness. NF-κB drives inflammation and resistance to cell death. Mebendazole suppresses both — cutting off two of cancer’s main survival pathways.
5. It triggers apoptosis
Through multiple routes — mitochondrial stress, Bcl-2 modulation, caspase activation — mebendazole pushes cancer cells from “survive” to “die.”
6. It blocks angiogenesis
Mebendazole also suppresses VEGF signaling, cutting off the tumor’s ability to grow new blood vessels and feed itself.
This is one drug doing the work of multiple targeted therapies, simultaneously, for a few cents a day.
The Bonus — Mebendazole and Insulin
This is something almost no one talks about.
Mebendazole has been shown to stimulate pancreatic beta cells, producing a 2 to 3-fold increase in insulin release.
For pancreatic cancer patients, this is significant. Many pancreatic cancer patients develop diabetes — either because the cancer damages the insulin-producing parts of the pancreas, or because of the metabolic chaos that comes with the disease. Mebendazole may help restore some of that lost function.
It is also potentially useful in type 1 and type 2 diabetes — but that is a different discussion.
The point here is that mebendazole is not just attacking the cancer. It is also addressing one of the most damaging complications of pancreatic cancer at the same time.
The Bottom Line
Pancreatic cancer has one of the worst survival rates of any cancer.
The medical system’s answer costs hundreds of thousands of dollars and adds a few months.
Mebendazole costs pennies. It dismantles the shield that blocks all other treatments. It hits multiple cancer pathways. And it supports insulin secretion at the same time.
It will never be mentioned in your oncologist’s office. There is no profit in it. No patent. No marketing budget. No conference talks sponsored by a pharmaceutical company.
But it should be in every pancreatic cancer conversation.
Mebendazole is a core component of the Targeted Metabolic Therapy protocol — especially for pancreatic and brain cancers. Combined with diet, fasting, other repurposed drugs, and the rest of the protocol, it gives patients a real chance at something the billion-dollar drugs cannot deliver.
This article is for education only and does not replace medical advice. Always work with a qualified healthcare professional experienced in metabolic oncology when designing a cancer protocol — especially for pancreatic cancer, where coordination with conventional care is critical.
Dr. Yahia Anane, PhD — drananeyahia.com
